{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:01:39Z","timestamp":1775746899028,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic sclerosis (SSc) is an autoimmune disease characterized by an excessive production and accumulation of collagen in the skin and internal organs often associated with interstitial lung disease (ILD). Its pathogenetic mechanisms are unknown and the lack of animal models mimicking the features of the human disease is creating a gap between the selection of anti-fibrotic drug candidates and effective therapies. In this work, we intended to pharmacologically validate a SSc-ILD model based on 1\u00a0week infusion of bleomycin (BLM) by osmotic minipumps in C57\/BL6 mice, since it will serve as a tool for secondary drug screening. Nintedanib (NINT) has been used as a reference compound to investigate antifibrotic activity either for lung or skin fibrosis. Longitudinal Micro-CT analysis highlighted a significant slowdown in lung fibrosis progression after NINT treatment, which was confirmed by histology. However, no significant effect was observed on lung hydroxyproline content, inflammatory infiltrate and skin lipoatrophy. The modest pharmacological effect reported here could reflect the clinical outcome, highlighting the reliability of this model to better profile potential clinical drug candidates. The integrative approach presented herein, which combines longitudinal assessments with endpoint analyses, could be harnessed in drug discovery to generate more reliable, reproducible and robust readouts.<\/jats:p>","DOI":"10.1038\/s41598-021-97728-z","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T10:02:41Z","timestamp":1631786561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["SSC-ILD mouse model induced by osmotic minipump delivered bleomycin: effect of Nintedanib"],"prefix":"10.1038","volume":"11","author":[{"given":"Francesca","family":"Ravanetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Ferrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Ragionieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Khalajzeyqami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Nicastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanto","family":"Ridwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Kleinjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino","family":"Villetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco Fabio","family":"Stellari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"97728_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00296-016-3636-7","volume":"37","author":"R Giacomelli","year":"2017","unstructured":"Giacomelli, R. et al. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol. Int. 37, 853\u2013863 (2017).","journal-title":"Rheumatol. Int."},{"key":"97728_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.semcdb.2019.12.007","volume":"101","author":"Y Asano","year":"2020","unstructured":"Asano, Y. & Varga, J. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies. Semin. Cell Dev. Biol. 101, 146\u2013160 (2020).","journal-title":"Semin. Cell Dev. Biol."},{"key":"97728_CR3","first-page":"111","volume":"21","author":"F Meloni","year":"2004","unstructured":"Meloni, F. et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc. Diffus. Lung. Dis. 21, 111\u2013118 (2004).","journal-title":"Sarcoidosis Vasc. Diffus. Lung. Dis."},{"key":"97728_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen, V. D. & Medsger, T. A. Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann. Rheum. Dis. 66, 940\u2013944 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"97728_CR5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek, M. & Cottin, V. Spectrum of fibrotic lung diseases. N. Engl. J. Med. 383, 958\u2013968 (2020).","journal-title":"N. Engl. J. Med."},{"key":"97728_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1165\/rcmb.2005-0062TR","volume":"33","author":"F Chua","year":"2005","unstructured":"Chua, F., Gauldie, J. & Laurent, G. J. Pulmonary fibrosis: Searching for model answers. Am. J. Respir. Cell Mol. Biol. 33, 9\u201313 (2005).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"97728_CR7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/MAJ.0b013e31821aa000","volume":"341","author":"A Degryse","year":"2011","unstructured":"Degryse, A. & Lawson, W. Progress toward improving animal models for idiopathic pulmonary fibrosis. Am. J. Med. Sci. 341, 444\u2013449 (2011).","journal-title":"Am. J. Med. Sci."},{"key":"97728_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1165\/rcmb.2013-0094TR","volume":"49","author":"BB Moore","year":"2013","unstructured":"Moore, B. B. et al. Animal models of fibrotic lung disease. Am. J. Respir. Cell Mol. Biol. 49, 167\u2013179 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"97728_CR9","doi-asserted-by":"publisher","first-page":"L439","DOI":"10.1152\/ajplung.00258.2010","volume":"299","author":"CJ Scotton","year":"2010","unstructured":"Scotton, C. J. & Chambers, R. C. Bleomycin revisited: towards a more representative model of IPF?. Am. J. Physiol. Lung Cell. Mol. Physiol. 299, L439\u2013L441 (2010).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"97728_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MCP.0b013e328349ac2b","volume":"17","author":"M Mouratis","year":"2011","unstructured":"Mouratis, M. & Aidinis, V. Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 17, 355\u2013361 (2011).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"97728_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas, A., Silver, R., Arrossi, A. & Highland, K. Systemic sclerosis-associated interstitial lung disease. Lancet Respir. Med. 8, 304\u2013320 (2020).","journal-title":"Lancet Respir. Med."},{"key":"97728_CR12","first-page":"1987","volume":"243","author":"J Harrison","year":"1987","unstructured":"Harrison, J. & Lazo, J. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther. 243, 1987 (1987).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"97728_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1164\/rccm.201103-0561OC","volume":"185","author":"Y Aono","year":"2012","unstructured":"Aono, Y. et al. Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am. J. Respir. Crit. Care Med. 185, 525\u2013536 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"97728_CR14","doi-asserted-by":"publisher","first-page":"L736","DOI":"10.1152\/ajplung.00210.2013","volume":"306","author":"R Lee","year":"2014","unstructured":"Lee, R. et al. Bleomycin delivery by osmotic minipump: Similarity to human scleroderma interstitial lung disease. Am. J. Physiol. Lung. Cell Mol. Physiol. 306, L736\u2013L748 (2014).","journal-title":"Am. J. Physiol. Lung. Cell Mol. Physiol."},{"key":"97728_CR15","doi-asserted-by":"publisher","first-page":"L376","DOI":"10.1152\/ajplung.00311.2019","volume":"318","author":"F Ravanetti","year":"2020","unstructured":"Ravanetti, F. et al. Modeling pulmonary fibrosis through bleomycin delivered by osmotic minipump: A new histomorphometric method of evaluation. Am. J. Physiol. Cell Mol. Physiol. 318, L376-385 (2020).","journal-title":"Am. J. Physiol. Cell Mol. Physiol."},{"key":"97728_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/labinvest.2014.145","volume":"95","author":"M Liang","year":"2015","unstructured":"Liang, M. et al. A modified murine model of systemic sclerosis: Bleomycin given by pump infusion induced skin and pulmonary inflammation and fibrosis. Lab. Invest. 95, 342\u2013350 (2015).","journal-title":"Lab. Invest."},{"key":"97728_CR17","first-page":"1","volume":"12","author":"T Watanabe","year":"2017","unstructured":"Watanabe, T. et al. Optimization of a murine and human tissue model to recapitulate dermal and pulmonary features of systemic sclerosis. PLoS ONE 12, 1\u201314 (2017).","journal-title":"PLoS ONE"},{"key":"97728_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14397595.2019.1696505","volume":"30","author":"M Kuwana","year":"2020","unstructured":"Kuwana, M. & Azuma, A. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. Mod. Rheumatol. 30, 225\u2013231 (2020).","journal-title":"Mod. Rheumatol."},{"key":"97728_CR19","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518\u20132528 (2019).","journal-title":"N. Engl. J. Med."},{"key":"97728_CR20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin, L. et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 45, 1434\u20131445 (2015).","journal-title":"Eur. Respir. J."},{"key":"97728_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","volume":"75","author":"J Huang","year":"2016","unstructured":"Huang, J. et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann. Rheum. Dis. 75, 883\u2013890 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"97728_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10456-017-9543-z","volume":"20","author":"M Ackermann","year":"2017","unstructured":"Ackermann, M. et al. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis 20, 359\u2013372 (2017).","journal-title":"Angiogenesis"},{"key":"97728_CR23","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3389\/fphar.2020.01117","volume":"11","author":"F Ruscitti","year":"2020","unstructured":"Ruscitti, F. et al. Quantification of lung fibrosis in IPF-like mouse model and pharmacological response to treatment by micro-computed tomography. Front. Pharmacol. 11, 2020 (2020).","journal-title":"Front. Pharmacol."},{"key":"97728_CR24","doi-asserted-by":"publisher","first-page":"1901105","DOI":"10.1183\/13993003.01105-2019","volume":"55","author":"P Kolb","year":"2020","unstructured":"Kolb, P. et al. The importance of interventional timing in the bleomycin model of pulmonary fibrosis. Eur. Respir. J. 55, 1901105 (2020).","journal-title":"Eur. Respir. J."},{"key":"97728_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1165\/rcmb.2017-0096ST","volume":"56","author":"RG Jenkins","year":"2017","unstructured":"Jenkins, R. G. et al. An official American thoracic society workshop report: Use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 56, 667\u2013679 (2017).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"97728_CR26","first-page":"208","volume":"39","author":"K Bayne","year":"1996","unstructured":"Bayne, K. Revised guide for the care and use of laboratory animals available. Am. Physiol. Soc. Physiol. 39, 208\u2013211 (1996).","journal-title":"Am. Physiol. Soc. Physiol."},{"key":"97728_CR27","first-page":"1","volume":"18","author":"NP du Sert","year":"2020","unstructured":"du Sert, N. P. et al. The arrive guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 18, 1\u201312 (2020).","journal-title":"PLoS Biol."},{"key":"97728_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11307-016-1026-x","volume":"19","author":"J Meganck","year":"2017","unstructured":"Meganck, J. & Liu, B. Dosimetry in micro-computed tomography: a review of the measurement methods, impacts, and characterization of the quantum GX imaging system. Mol. Imaging Biol. 19, 499\u2013511 (2017).","journal-title":"Mol. Imaging Biol."},{"key":"97728_CR29","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1164\/ajrccm.164.9.2103121","volume":"164","author":"L Gattinoni","year":"2001","unstructured":"Gattinoni, L., Caironi, P., Pelosi, P. & Goodman, L. R. What has computed tomography taught us about the acute respiratory distress syndrome?. Am. J. Respir. Crit. Care Med. 164, 1701\u20131711 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"97728_CR30","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41598-020-71293-3","volume":"10","author":"L Mecozzi","year":"2020","unstructured":"Mecozzi, L. et al. In-vivo lung fibrosis staging in a bleomycin-mouse model: a new micro-CT guided densitometric approach. Sci. Rep. 10, 2020 (2020).","journal-title":"Sci. Rep."},{"key":"97728_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0029399","volume":"6","author":"P Gallet","year":"2011","unstructured":"Gallet, P. et al. Long-term alterations of cytokines and growth factors expression in irradiated tissues and relation with histological severity scoring. PLoS ONE 6, 1\u201310 (2011).","journal-title":"PLoS ONE"},{"key":"97728_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40248-017-0089-0","volume":"12","author":"F Ruscitti","year":"2017","unstructured":"Ruscitti, F. et al. Longitudinal assessment of bleomycin-induced lung fibrosis by Micro-CT correlates with histological evaluation in mice. Multidiscip. Respir. Med. 12, 8 (2017).","journal-title":"Multidiscip. Respir. Med."},{"key":"97728_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10111585","volume":"10","author":"GE Courtoy","year":"2020","unstructured":"Courtoy, G. E. et al. Digital image analysis of picrosirius red staining: A robust method for multi-organ fibrosis quantification and characterization. Biomolecules 10, 1\u201323 (2020).","journal-title":"Biomolecules"},{"key":"97728_CR34","first-page":"1","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program. Sci. Adv. 19, 1\u201313 (2020).","journal-title":"Sci. Adv."},{"key":"97728_CR35","first-page":"2020","volume":"203","author":"S Brody","year":"2020","unstructured":"Brody, S. et al. Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis. A clinical trial. Am. J. Respir. Crit. Care Med. 203, 2020 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"97728_CR36","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","volume":"76","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann. Rheum. Dis. 76, 1941\u20131948 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"97728_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.intimp.2019.03.061","volume":"72","author":"N Bellamri","year":"2019","unstructured":"Bellamri, N. et al. Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib. Int. Immunopharmacol. 72, 112\u2013123 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"97728_CR38","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1152\/ajplung.2000.279.3.L562","volume":"279","author":"M Selman","year":"2000","unstructured":"Selman, M. et al. A prevailing nondegradative lung microenvironment\u202f?. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, 562\u2013574 (2000).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"97728_CR39","first-page":"317","volume":"50","author":"T Oggionni","year":"2006","unstructured":"Oggionni, T. et al. Time course of matrix metalloproteases and tissue inhibitors in bleomycin-induced pulmonary fibrosis. Eur. J. Histochem. 50, 317\u2013325 (2006).","journal-title":"Eur. J. Histochem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97728-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97728-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97728-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:31:03Z","timestamp":1670081463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97728-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97728"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97728-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GV, AG and FS are employees of Chiesi Farmaceutici S.p.A., that supported the research work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18513"}}